These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 13330188)

  • 21. Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets.
    Liu L; Freedman J; Hornstein A; Dewar L; Blajchman MA; Ofosu FA
    Br J Haematol; 1996 Feb; 92(2):458-65. PubMed ID: 8603017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin.
    Anonick PK; Gonias SL
    Biochem J; 1991 Apr; 275 ( Pt 1)(Pt 1):53-9. PubMed ID: 1708234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly potent fibrinolytic serine protease from Streptomyces.
    Uesugi Y; Usuki H; Iwabuchi M; Hatanaka T
    Enzyme Microb Technol; 2011 Jan; 48(1):7-12. PubMed ID: 22112764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fibrinolytic and thrombolytic properties of plasmin (a preparation of streptolyase-activated plasminogen)].
    Andreenko GV; Murav'eva NF; Kanygina ED; Liutova LV; Karabasova MA
    Gematol Transfuziol; 1986 Mar; 31(3):27-32. PubMed ID: 2941333
    [No Abstract]   [Full Text] [Related]  

  • 25. Profibrinolysin, antifibrinolysin, fibrinogen and urine fibrinolytic factors in the human subject.
    GUEST MM
    J Clin Invest; 1954 Nov; 33(11):1553-9. PubMed ID: 13211809
    [No Abstract]   [Full Text] [Related]  

  • 26. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
    Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
    Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modified fibrinolytic technique for analysis of the plasmin system.
    MAXWELL RE; LEWANDOWSKI V
    Anal Biochem; 1962 Nov; 4():407-12. PubMed ID: 13934069
    [No Abstract]   [Full Text] [Related]  

  • 28. Contact and plasmin kinin-forming systems in the blood.
    Buluk K; Czokalo M; Malofiejew M
    Thromb Diath Haemorrh; 1970 Dec; 24(3):548-58. PubMed ID: 4251262
    [No Abstract]   [Full Text] [Related]  

  • 29. [Evaluation of plasmin and trypsin by means of fibrinolytic and fibrinogenolytic methods].
    CURT BOECKEL CR
    Sem Med; 1961 Oct; 119():1315-7. PubMed ID: 13882747
    [No Abstract]   [Full Text] [Related]  

  • 30. Mafenide (Sulfamylon) inhibits plasmin fibrinolytic activity.
    Weisdorf DJ; Aldridge JH
    Thromb Haemost; 1988 Jun; 59(3):440-4. PubMed ID: 2973151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
    Liu JN; Gurewich V
    J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [THROMBOLYTIC THERAPY AND CHANGES IN FIBRINOLYTIC ACTIVITY].
    DOUGLAS AS; MCNICOL GP
    Recenti Prog Med; 1964 Sep; 37():189-217. PubMed ID: 14229145
    [No Abstract]   [Full Text] [Related]  

  • 33. Unknown properties of the products of plasmin-degradation of fibrinogen and fibrin.
    Buluk K; Malofiejew M; Czokalo M
    Bull Acad Pol Sci Biol; 1966; 14(4):193-7. PubMed ID: 4223765
    [No Abstract]   [Full Text] [Related]  

  • 34. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
    Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
    Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relation between degree of fibrinogen proteolysis by plasmin and fibrinolytic paracoagulation.
    SZUCHET S; DERECHIN M
    Proc Soc Exp Biol Med; 1957 Feb; 94(2):267-9. PubMed ID: 13408230
    [No Abstract]   [Full Text] [Related]  

  • 36. Relative proteolysis of the fibrinogen B beta chain by thrombin and plasmin as a determinant of thrombosis.
    Nossel HL
    Nature; 1981 May; 291(5811):165-7. PubMed ID: 6453297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction.
    Goto S; Kawai Y; Abe S; Takahashi E; Handa S; Ogawa S; Watanabe K; Hori S; Ikeda Y
    Angiology; 1994 Apr; 45(4):273-81. PubMed ID: 8161005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A method using fibrin-fixed Blue Dextran for determining the plasmin and plasmin inhibitor activities in human plasma.
    Tamura Y; Otsuka A; Sone K; Sakurai E; Mori H; Sumi H; Kosugi T; Fujii S
    Biochim Biophys Acta; 1978 Jul; 525(1):194-9. PubMed ID: 150858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis.
    Smith RA; Dupe RJ; English PD; Green J
    Thromb Haemost; 1982 Jun; 47(3):269-74. PubMed ID: 6214039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The small caliber prosthesis provided healing characteristics by plasmin-treated fibrin: preliminary report].
    Shinhara R; Fukuda Y; Haruta N; Kagawa N; Dohi K; Takano Y; Ezaki Y
    Nihon Geka Gakkai Zasshi; 1992 Nov; 93(11):1452. PubMed ID: 1448054
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.